Figure 2.

Statin treatment reduces levels of monocyte activation. Plasma samples were thawed and levels of soluble CD14 (sCD14) were measured by enzyme-linked immunosorbent assay. A, Patients receiving statin treatment had a relative reduction in sCD14 levels from baseline (13.4%), whereas patients receiving placebo had an increase in sCD14 levels (1.2%), and this difference was significant between groups (P = .0017). B, Tissue factor (TF) expression on patrolling (CD14^DimCD16⁺) monocytes was also reduced by statin treatment (−38.8%), and this change differed significantly from the change measured in the placebo arm (11.9%, P = .04).